For providers

Peptide Research for Providers

A searchable reference to published research on peptides, for licensed prescribers and their teams. Educational reference only.

A physician on a video visit. The photograph is illustrative, not Sirius staff.

Clinical review pending. This page has not yet been reviewed by a licensed clinician, and we would rather say so than print a name that does not exist.

Tesamorelin

Mechanism summary
It is studied as a growth hormone releasing hormone receptor agonist. The trials report growth hormone and insulin like growth factor 1 measurements. This page does not turn those measurements into a clinical instruction.
Research context
Tesamorelin is a synthetic analog of growth hormone releasing hormone. Randomized trials have enrolled adults with HIV and abdominal fat accumulation and recorded visceral fat, liver fat, and laboratory markers. A 2014 randomized trial recorded visceral fat and liver fat. A pooled analysis of two earlier trials and a 2008 report recorded abdominal fat and the events observed over a longer interval. This summary does not interpret those measurements as a promise of results.
Regulatory status
Drugs@FDA records the approval of EGRIFTA (tesamorelin for injection) on November 10, 2010, under application 022505. Drugs@FDA states that this former NDA was deemed to be a BLA on March 23, 2020, and lists its products with a prescription marketing status. The most recent labeling posted under that application, revised in March 2025, is for EGRIFTA WR and states that it is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. That approval covers the EGRIFTA products under that application and their labeled use. It is not an approval of other preparations containing tesamorelin.
Primary sources

Sermorelin

Mechanism summary
It is studied as a growth hormone releasing hormone receptor agonist. The reviews describe stimulation of growth hormone release as the mechanism class.
Research context
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth hormone releasing hormone. Reviews discuss published research on growth hormone secretion, including studies in children with idiopathic growth hormone deficiency and commentary on adult research. A 1999 review summarizes published studies in children with idiopathic growth hormone deficiency. A 2006 editorial discusses adult research. A 1995 paper recorded growth measurements in children during a study of this 29 amino acid sequence. This page does not turn those measurements into a recommendation.
Regulatory status
Drugs@FDA records the approval of GEREF (sermorelin acetate) injection under NDA 019863 on December 28, 1990, and under NDA 020443 on September 26, 1997. Drugs@FDA lists every GEREF product as discontinued. In a Federal Register notice published March 4, 2013, FDA determined that these GEREF products were not withdrawn for reasons of safety or effectiveness.
Primary sources

GHK-Cu

Mechanism summary
Copper binding is the mechanism class. The reviews discuss gene expression and cell signals reported in laboratory models. Those reviews do not establish a clinical outcome.
Research context
GHK-Cu is a complex of the tripeptide glycyl histidyl lysine with copper. Reviews describe the peptide in human plasma and in skin and gene expression research. A separate chemistry paper uses the tripeptide as a copper binding sequence. A 2018 review and a 2015 review discuss GHK in published laboratory and skin research. This page does not restate outcomes from the studies those reviews cite. A 2001 chemistry paper uses glycyl histidyl lysine as a copper binding sequence in a fluorescent assay.
Regulatory status
FDA's list of bulk drug substances nominated under section 503A of the FD&C Act, updated May 14, 2026, lists GHK-Cu (except for injectable routes of administration) in category 1, bulk drug substances under evaluation. The same document says GHK-Cu was removed from category 1 on April 22, 2026, because its nominations were withdrawn, and was added back for non-injectable routes after one nominator clarified on May 5, 2026 that it meant to withdraw only its nomination for the injectable route. FDA says it intends to consult its advisory committee (PCAC) before the end of February 2027 about the potential inclusion of GHK-Cu on the 503A bulks list. Category 1 is a list of substances under evaluation, not a list of approved products.
Primary sources

Bremelanotide

Mechanism summary
Melanocortin receptor agonism is the mechanism class. A separate paper recorded ambulatory blood pressure in people studied with this peptide.
Research context
Bremelanotide is a synthetic peptide studied as a melanocortin receptor agonist. The same peptide is called PT-141 in earlier papers. Two randomized trials enrolled premenopausal women with hypoactive sexual desire disorder and recorded desire scores and adverse events. Two phase 3 randomized trials recorded desire scores and adverse events. An earlier paper recorded subjective sexual response scores in premenopausal women with sexual arousal disorder. This page does not interpret those scores as a promise of results. A 2017 paper describes ambulatory blood pressure monitoring in a study of this peptide.
Regulatory status
Drugs@FDA records the approval of VYLEESI, a bremelanotide injection, under NDA 210557 on June 21, 2019, and lists it with a prescription marketing status. The labeling revised in October 2026 states that it is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, within the limits the label describes. That approval covers the VYLEESI products under that application and their labeled use. It is not an approval of other preparations containing bremelanotide.
Primary sources

Gonadorelin

Mechanism summary
It binds the gonadotropin releasing hormone receptor on pituitary gonadotrophs. The physiology papers describe release of luteinizing hormone and follicle stimulating hormone. A 2018 review surveys analogs in this receptor class.
Research context
Gonadorelin is a synthetic form of gonadotropin releasing hormone, a decapeptide. Reviews describe the native hormone and analogs in reproductive endocrinology. A 1991 review describes gonadotropin releasing hormone and its analogs. A 2018 review surveys analog research in this receptor class. This page does not compare preparations.
Regulatory status
Drugs@FDA records the approval of FACTREL (gonadorelin hydrochloride) under NDA 018123 on September 30, 1982, and of LUTREPULSE (gonadorelin acetate) under NDA 019687 on October 10, 1989. It lists both products as discontinued.
Primary sources

Elamipretide

Mechanism summary
The 2025 review describes a mitochondrial mechanism involving cardiolipin. A 2023 laboratory paper reports adenine nucleotide translocator measurements in aged mitochondria. This page does not turn those measurements into a clinical instruction.
Research context
Elamipretide is a synthetic tetrapeptide. A 2025 review describes its structure and a mitochondrial mechanism. A 2023 randomized trial recorded functional measures in primary mitochondrial myopathy. A 2023 laboratory paper reports measurements in isolated mitochondria. This page does not interpret those records as a promise of results.
Regulatory status
Drugs@FDA records the approval of FORZINITY (elamipretide) under NDA 215244 on September 19, 2025, with priority review and orphan status, and lists it with a prescription marketing status. Its labeling states that it is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg, and that this indication is approved under accelerated approval. That approval covers the FORZINITY products under that application and their labeled use. It is not an approval of other preparations containing elamipretide.
Primary sources